Daxor Co. (NASDAQ:DXR) CEO Michael Richard Feldschuh Buys 3,360 Shares

Daxor Co. (NASDAQ:DXR) CEO Michael Richard Feldschuh bought 3,360 shares of Daxor stock in a transaction dated Monday, March 10th. The stock was acquired at an average cost of $7.68 per share, with a total value of $25,804.80. Following the transaction, the chief executive officer now owns 210,852 shares of the company’s stock, valued at $1,619,343.36. This trade represents a 1.62 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Daxor Price Performance

Shares of Daxor stock opened at $7.79 on Wednesday. The firm has a 50-day moving average of $7.75 and a 200-day moving average of $8.49. Daxor Co. has a 52-week low of $6.55 and a 52-week high of $10.00.

Institutional Investors Weigh In On Daxor

An institutional investor recently raised its position in Daxor stock. Keyes Stange & Wooten Wealth Management LLC increased its position in shares of Daxor Co. (NASDAQ:DXR) by 34.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,612 shares of the company’s stock after purchasing an additional 3,771 shares during the quarter. Keyes Stange & Wooten Wealth Management LLC owned 0.30% of Daxor worth $126,000 at the end of the most recent reporting period. 1.34% of the stock is currently owned by hedge funds and other institutional investors.

Daxor Company Profile

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.